A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

被引:110
作者
Zhang, W.
Winder, T.
Ning, Y.
Pohl, A.
Yang, D. [2 ]
Kahn, M.
Lurje, G. [3 ]
LaBonte, M. J. [4 ]
Wilson, P. M. [4 ]
Gordon, M. A.
Hu-Lieskovan, S.
Mauro, D. J. [6 ]
Langer, C. [5 ]
Rowinsky, E. K. [7 ]
Lenz, H. -J. [1 ,2 ]
机构
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Sharon A Carpenter Lab,Div Med Oncol, Los Angeles, CA 90033 USA
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[3] Univ Zurich Hosp, Dept Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland
[4] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA
[5] Bristol Myers Squibb Pharmaceut Ltd, Early Oncol, New York, NY USA
[6] Merck & Co Inc, Oncol, Whitehouse Stn, NJ USA
[7] ImClone Syst, Oncol, New York, NY USA
关键词
cetuximab; KRAS; microRNA polymorphism; metastatic colon cancer; GROWTH-FACTOR-RECEPTOR; SINGLE-AGENT CETUXIMAB; PLUS IRINOTECAN; CLINICAL-RESPONSE; COLON-CANCER; LUNG-CANCER; COPY NUMBER; PHASE-II; K-RAS; OXALIPLATIN;
D O I
10.1093/annonc/mdq315
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Recent studies have found that KRAS mutations predict resistance to monoclonal antibodies targeting the epidermal growth factor receptor in metastatic colorectal cancer (mCRC). A polymorphism in a let-7 microRNA complementary site (lcs6) in the KRAS 3' untranslated region (UTR) is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival (OS) in oral cancers. We tested the hypothesis whether this polymorphism may be associated with clinical outcome in KRAS wild-type (KRASwt) mCRC patients treated with cetuximab monotherapy. Patients and methods: The presence of KRAS let-7 lcs6 polymorphism was evaluated in 130 mCRC patients who were enrolled in a phase II study of cetuximab monotherapy (IMCL-0144). Genomic DNA was extracted from dissected formalin-fixed paraffin-embedded tumor tissue, KRAS mutation status and polymorphism were assessed using direct sequencing and PCR restriction fragment length polymorphism technique. Results: KRAS let-7 lcs6 polymorphism was found to be related to object response rate (ORR) in mCRC patients whose tumors had KRASwt. The 12 KRASwt patients harboring at least a variant G allele (TG or GG) had a 42% ORR compared with a 9% ORR in 55 KRASwt patients with let-7 lcs6 TT genotype (P = 0.02, Fisher's exact test). KRASwt patients with TG/GG genotypes had trend of longer median progression-free survival (3.9 versus 1.3 months) and OS (10.7 versus 6.4 months) compared to those with TT genotypes. Conclusions: These results are the first to indicate that the KRAS 3' UTR polymorphism may predict for cetuximab responsiveness in KRASwt mCRC patients, which warrants validation in other clinical trials.
引用
收藏
页码:104 / 109
页数:6
相关论文
共 29 条
[1]   let-7 microRNA functions as a potential growth suppressor in human colon cancer cells [J].
Akao, Yukihiro ;
Nakagawa, Yoshihito ;
Naoe, Tomoki .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (05) :903-906
[2]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[3]   Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan [J].
Bibeau, Frederic ;
Lopez-Crapez, Evelyne ;
Di Fiore, Frederic ;
Thezenas, Simon ;
Ychou, Marc ;
Blanchard, France ;
Lamy, Aude ;
Penault-Llorca, Frederique ;
Frebourg, Thierry ;
Michel, Pierre ;
Sabourin, Jean-Christophe ;
Boissiere-Michot, Florence .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1122-1129
[4]   Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].
Bokemeyer, Carsten ;
Bondarenko, Igor ;
Makhson, Anatoly ;
Hartmann, Joerg T. ;
Aparicio, Jorge ;
de Braud, Filippo ;
Donea, Serban ;
Ludwig, Heinz ;
Schuch, Gunter ;
Stroh, Christopher ;
Loos, Anja H. ;
Zubel, Angela ;
Koralewski, Piotr .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671
[5]   A SNP in a let-7 microRNA Complementary Site in the KRAS 3′ Untranslated Region Increases Non-Small Cell Lung Cancer Risk [J].
Chin, Lena J. ;
Ratner, Elena ;
Leng, Shuguang ;
Zhai, Rihong ;
Nallur, Sunitha ;
Babar, Imran ;
Muller, Roman-Ulrich ;
Straka, Eva ;
Su, Li ;
Burki, Elizabeth A. ;
Crowell, Richard E. ;
Patel, Rajeshvari ;
Kulkarni, Trupti ;
Homer, Robert ;
Zelterman, Daniel ;
Kidd, Kenneth K. ;
Zhu, Yong ;
Christiani, David C. ;
Belinsky, Steven A. ;
Slack, Frank J. ;
Weidhaas, Joanne B. .
CANCER RESEARCH, 2008, 68 (20) :8535-8540
[6]   A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers [J].
Christensen, Brock C. ;
Moyer, Benjamin J. ;
Avissar, Michele ;
Ouellet, Lauren G. ;
Plaza, Silvia L. ;
McClean, Michael D. ;
Marsit, Carmen J. ;
Kelsey, Karl T. .
CARCINOGENESIS, 2009, 30 (06) :1003-1007
[7]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[8]   Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].
Di Fiore, F. ;
Blanchard, F. ;
Charbonnier, F. ;
Le Pessot, F. ;
Lamy, A. ;
Galais, M. P. ;
Bastit, L. ;
Killian, A. ;
Sesboue, R. ;
Tuech, J. J. ;
Queuniet, A. M. ;
Paillot, B. ;
Sabourin, J. C. ;
Michot, F. ;
Michel, P. ;
Frebourg, T. .
BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169
[9]   Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab [J].
Jacobs, Bart ;
De Roock, Wendy ;
Piessevaux, Hubert ;
Van Oirbeek, Robin ;
Biesmans, Bart ;
De Schutter, Jef ;
Fieuws, Steffen ;
Vandesompele, Jo ;
Peeters, Marc ;
Van Laethem, Jean-Luc ;
Humblet, Yves ;
Penault-Llorca, Frederique ;
De Hertogh, Gert ;
Laurent-Puig, Pierre ;
Van Cutsem, Eric ;
Tejpar, Sabine .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :5068-5074
[10]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]